BRPI0816064A2 - Inibidores da atividade de proteína tirosina cinase. - Google Patents

Inibidores da atividade de proteína tirosina cinase.

Info

Publication number
BRPI0816064A2
BRPI0816064A2 BRPI0816064A BRPI0816064A2 BR PI0816064 A2 BRPI0816064 A2 BR PI0816064A2 BR PI0816064 A BRPI0816064 A BR PI0816064A BR PI0816064 A2 BRPI0816064 A2 BR PI0816064A2
Authority
BR
Brazil
Prior art keywords
inhibitors
tyrosine kinase
kinase activity
protein tyrosine
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen William Claridge
Ljubomir Isakovic
Michael Mannion
Stéphane Raeppel
Oscar Mario Saavedra
Frédéric Gaudette
Lijie Zhan
Nancy Z Zhou
Franck Raeppel
Robert Deziel
Arkadii Vaisburg
Tetsuyuki Uno
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of BRPI0816064A2 publication Critical patent/BRPI0816064A2/pt
Publication of BRPI0816064B1 publication Critical patent/BRPI0816064B1/pt
Publication of BRPI0816064B8 publication Critical patent/BRPI0816064B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
BRPI0816064A 2007-08-29 2008-08-28 composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica BRPI0816064B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29
PCT/CA2008/001538 WO2009026717A1 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Publications (3)

Publication Number Publication Date
BRPI0816064A2 true BRPI0816064A2 (pt) 2015-03-31
BRPI0816064B1 BRPI0816064B1 (pt) 2020-01-28
BRPI0816064B8 BRPI0816064B8 (pt) 2021-05-25

Family

ID=40386626

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816064A BRPI0816064B8 (pt) 2007-08-29 2008-08-28 composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica

Country Status (19)

Country Link
US (3) US8404846B2 (pt)
EP (1) EP2183254B1 (pt)
JP (1) JP5656634B2 (pt)
KR (1) KR101556269B1 (pt)
CN (3) CN109970759A (pt)
AR (1) AR068066A1 (pt)
AU (1) AU2008293038B2 (pt)
BR (1) BRPI0816064B8 (pt)
CA (1) CA2697795C (pt)
DK (1) DK2183254T3 (pt)
ES (1) ES2635131T3 (pt)
IL (1) IL204192A (pt)
MX (1) MX2010002427A (pt)
MY (1) MY156536A (pt)
PL (1) PL2183254T3 (pt)
RU (1) RU2495044C2 (pt)
TW (1) TWI571468B (pt)
WO (1) WO2009026717A1 (pt)
ZA (1) ZA201001512B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923670A2 (pt) * 2008-03-05 2013-07-30 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
RU2011142597A (ru) * 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. Производные сложных эфиров аминокислот, их соли и способы применения
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
JP2013503903A (ja) * 2009-09-03 2013-02-04 アラーガン インコーポレイテッド チロシンキナーゼモジュレーターとしての化合物
EP2563794A4 (en) * 2010-04-16 2013-12-04 Methylgene Inc INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
EP2621481B2 (en) * 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
JP2013540759A (ja) * 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
WO2012044577A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
JP6744309B2 (ja) 2014-12-02 2020-08-19 イグニタ，インコーポレイテッド 神経芽細胞腫の治療のための併用
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
BR112020000793A2 (pt) 2017-07-19 2020-07-14 Ignyta, Inc. composições farmacêuticas e formas de dosagem
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
EP3762392A4 (en) * 2018-03-08 2021-09-15 Wellmarker Bio Co., Ltd. THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
US20230172914A1 (en) 2019-09-06 2023-06-08 Wellmarker Bio Co., Ltd. Biomarker-based therapeutic composition
EP4027999A4 (en) * 2019-09-10 2023-08-16 Mirati Therapeutics, Inc. CRYSTALLINE FORM OF A MULTIPLE TYROSINE KINASE INHIBITOR, METHOD FOR PREPARATION AND USE
EP4061421A1 (en) * 2019-11-21 2022-09-28 BeiGene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
JP7434575B2 (ja) 2020-01-07 2024-02-20 メッドシャイン ディスカバリー インコーポレイテッド 重水素化チエノピリジン系化合物
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof
TW202342426A (zh) * 2022-02-15 2023-11-01 大陸商百濟神州（蘇州）生物科技有限公司 N-[(6-溴吡啶-3-基)甲基]-2-甲氧基乙烷-1-胺鹽及其製備方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
ES2318649T3 (es) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
NZ529046A (en) 2001-04-27 2005-10-28 Kirin Brewery Quinoline derivative having azolyl group and quinazoline derivative
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
NZ547517A (en) 2004-02-27 2009-04-30 Eisai R&D Man Co Ltd Novel pyridine and pyrimidine derivatives for hepatocyte growth and tumour inihibition
EP1732543B1 (en) * 2004-03-15 2017-05-10 PTC Therapeutics, Inc. Tetracyclic carboline deratives for inhibiting angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
CN101031570B (zh) * 2004-07-30 2012-09-05 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US8093264B2 (en) * 2005-05-20 2012-01-10 Methylgene Inc. Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
NZ563774A (en) 2005-05-20 2010-04-30 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
KR100950737B1 (ko) 2005-08-24 2010-03-31 에자이 알앤드디 매니지먼트 가부시키가이샤 신규 피리딘 유도체 및 피리미딘 유도체(3)
TW200806675A (en) * 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
CA2645137A1 (en) 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
JP2010507618A (ja) 2006-10-27 2010-03-11 グラクソ グループ リミテッド ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体
EP2563794A4 (en) * 2010-04-16 2013-12-04 Methylgene Inc INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS

Also Published As

Publication number Publication date
RU2010111729A (ru) 2011-10-10
MY156536A (en) 2016-02-26
CA2697795A1 (en) 2009-03-05
CN105777776A (zh) 2016-07-20
RU2495044C2 (ru) 2013-10-10
US20120108628A1 (en) 2012-05-03
KR101556269B1 (ko) 2015-09-30
US8389541B2 (en) 2013-03-05
AR068066A1 (es) 2009-11-04
PL2183254T3 (pl) 2017-10-31
US8404846B2 (en) 2013-03-26
EP2183254A1 (en) 2010-05-12
US20090264440A1 (en) 2009-10-22
AU2008293038A1 (en) 2009-03-05
CN109970759A (zh) 2019-07-05
CN105777776B (zh) 2021-06-08
ES2635131T3 (es) 2017-10-02
EP2183254B1 (en) 2017-06-21
DK2183254T3 (en) 2017-09-11
MX2010002427A (es) 2010-03-30
TW200914458A (en) 2009-04-01
CN101932586A (zh) 2010-12-29
EP2183254A4 (en) 2011-09-28
AU2008293038B2 (en) 2013-08-29
US8846927B2 (en) 2014-09-30
JP5656634B2 (ja) 2015-01-21
ZA201001512B (en) 2010-11-24
BRPI0816064B8 (pt) 2021-05-25
CA2697795C (en) 2016-08-16
WO2009026717A1 (en) 2009-03-05
US20130165477A1 (en) 2013-06-27
TWI571468B (zh) 2017-02-21
KR20100075873A (ko) 2010-07-05
BRPI0816064B1 (pt) 2020-01-28
IL204192A (en) 2016-08-31
JP2010536887A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
BRPI0816064A2 (pt) Inibidores da atividade de proteína tirosina cinase.
CY2019009I2 (el) Αναστολεις πρωτεϊνικων κινασων
CY2017012I1 (el) Αναστολεις κινασης τυροσινης bruton
BRPI0717317A2 (pt) Modularoes da proteína cinase triazalopiridazina
BRPI0910668A2 (pt) inibidores de proteína quinases
BRPI0810086A2 (pt) inibidores de tirosina quinase de bruton
BRPI0922224A2 (pt) composições de inibidores de proteína tirosina quiinase receptora.
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
ZA201007517B (en) Inhibitors of protein tyrosine kinase activity
ATE479434T1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
BR112012007300A2 (pt) derivador de pirimidina como inibidores proteína tirosina cinase 2
BRPI1009112A2 (pt) inibidores de tirosina quinase de bruton
BRPI0812360A2 (pt) Compostos moduladores de quinase heterocíclica e método de modulação da atividade de uma proteína tirosina quinase
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
BRPI0716781A2 (pt) Inibidores da quinase
ES2590905T8 (es) Inhibidores de la tirosina quinasa de Bruton
BRPI0714291A2 (pt) Derivados de [4,5']bipirimidinil-6-4'-diamina como inibidores de proteína cinase
BRPI0719797A2 (pt) compostos e composições como inibidores de proteína cinase
DK2848610T3 (da) Hæmmere af kinaseaktivitet
BRPI0817843A2 (pt) Inibidores da quinase c-fms
ATE455102T1 (de) Inhibitoren von akt (proteinkinase b)
BRPI0921509A2 (pt) inibidor triazolotiadiazol de proteína quinase c-met
ATE520664T1 (de) Tyrosinkinase-hemmer
BRPI0822522A2 (pt) Inibidores da proteína quinase ikk-beta serina- treonina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF